Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24296938 | 0.81 | — | — | |
| SCHEMBL22084732 | 0.79 | KDM4E (0.32) | ALDH1A1 | |
| SCHEMBL24361843 | 0.67 | KMT2A (0.30) | — | |
| SCHEMBL24296700 | 0.64 | PARP15 (0.39) | TRPA1LMNAALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL7899820 | 0.62 | POLB (0.34) | LMNA | |
| SCHEMBL22084279 | 0.62 | KCNMA1 (0.45) | LMNAALDH1A1TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL12258194 | 0.61 | LMNA (0.32) | LMNAALDH1A1TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL19531654 | 0.61 | BRD4 (0.34) | — | |
| SCHEMBL25481641 | 0.61 | MAPT (0.36) | ALDH1A1 | |
| SCHEMBL6127947 | 0.61 | ALDH1A1 (0.31) | ALDH1A1TSHRSMN1; SMN2NPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | SCOHIA PHARMA, INC. (JP) | 2022-12-06 | — | — | US | disclosed |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | SCOHIA PHARMA, INC. (JP) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518763-B2 | Macrocyclic compound and use thereof | TFAM, KEAP1, FASTKD1 | TRPA1 2286/4885LMNA 2953/4885CHRM1 2325/4885 |
| US-20220119391-A1 | MACROCYCLIC COMPOUND AND USE THEREOF | TFAM, KEAP1, CKMT1A; CKMT1B | TRPA1 2261/4885LMNA 2632/4885CHRM1 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.